WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory Challenges
Ouvrir ce répertoire et afficher son contenuEssential Medicines
Ouvrir ce répertoire et afficher son contenuSafety and Efficacy Issues
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuHerbal Medicines
Ouvrir ce répertoire et afficher son contenuRegulatory and Safety Action
Fermer ce répertoireConsultation Document
Afficher le documentThe International Pharmacopoeia - monographs for antiretrovirals
Afficher le documentIndinavir sulfate
Afficher le documentNelfinavir mesilate
Afficher le documentNevirapine anhydrous
Afficher le documentProposed International Nonproprietary Names: List 90
Afficher le documentRecommended International Nonproprietary Names: List 51
 

The International Pharmacopoeia - monographs for antiretrovirals

Within the framework of the Pilot Procurement Project for Quality and Sourcing of HIV Drugs (http://www.who.int/medicines), the International Pharmacopoeia is collaborating with manufacturers, independent analytical drug quality control laboratories, national and regional pharmacopoeial bodies, research, governments, and regulatory bodies to provide specifications and monographs for the following antiretroviral agents:

abacavir, didanosine, efavirenz, indinavir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, stavudine, zidovudine

Specifications for the respective dosage forms will be developed during a second phase of the project. The draft monographs, Indinavir sulfate, nelfinavir mesilate, and nevirapine are now available for consultation and are presented below. Comments should be sent to: Quality and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland or kopps@who.int.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012